News for Vaccitech plc (VACC)

CHIEF EXECUTIVE OFFICER'S STATEMENT I am pleased to report the Group's interim results for the six-month period ended 31 October 2023. During the period, Scancell...

Barinthus Bio names Leon Hooftman as new CMO

OXFORD, United Kingdom, March 20, 2024 -- Barinthus Biotherapeutics plc , formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the...

Earnings call: Arbutus Biopharma outlines HBV strategy and financial health

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...

CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine...

Barinthus Biotherapeutics (BRNS) stock fell 18% Tuesday, the day after it changed its name from Vaccitech and said it planned to present data on its hepatitis B drug at AASLD.

Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi…

Vaccitech (VACC) said that it has rebranded at Barinthus Therapeutics (BRNS) to reflect its expansion beyond developing vaccines. Read more here.

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid...

The United Kingdom, like the rest of the world, is facing the negative effects of the Russian invasion of Ukraine and rising inflation.

/PRNewswire/ --The influenza vaccine market is set to grow by USD 2.56 billion, at a CAGR of 8.66% from 2021 to 2026. The report offers an up-to-date analysis...

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.